with at least 10 colorectal adenomas by 60 years of age (Supplementary Table 1 ). For three probands, a relative with more than five adenomas was also sequenced, and, for one proband, two additional affected relatives were sequenced. Eight of the 20 sequenced individuals had developed CRC, and all of the remaining individuals had a firstdegree relative with CRC. Known Mendelian cancer syndromes had reportedly been excluded previously in the clinical diagnostic setting by screening for mutations in APC, MUTYH and the mismatch repair genes, together with microsatellite instability (MSI) testing and immunohistochemistry for mismatch repair proteins in some cases. The pedigrees of the 15 families showed a degree of heterogeneity in their phenotypes and patterns of inheritance, and we anticipated that this might reflect underlying genetic heterogeneity.
RESULTS

Identification of colorectal tumor susceptibility variants
After applying standard quality assurance procedures, wholegenome sequencing reads were mapped and called using the established local pipeline based on the STAMPY 1 and Platypus programs (Online Methods). We initially excluded two individuals who were found, despite previous testing, to have pathogenic heterozygous germline mutations in genes known to cause high-penetrance predisposition to colorectal tumors (Supplementary Table 1) . One of these individuals had attenuated familial adenomatous polyposis (FAP) owing to a splice-site germline mutation in the APC gene (c.423-2A>G), and the other had Lynch syndrome caused by an MSH6 mutation (encoding a p.Arg911* alteration).
In the absence of information regarding the underlying genetic architecture of the multiple-adenoma phenotype, including the mode of inheritance in our families, we treated analysis of the remaining 13 families analyzed by whole-genome sequencing as the discovery phase of our project. We then used a pragmatic approach to prioritize genes for further investigation in a larger validation phase of individuals with a similar phenotype. On the assumption that at least some individuals would carry mutations with direct, strong effects on protein function, we then filtered the data so as to examine only protein-coding or splice-site variants. We filtered variants further using the algorithm shown in Supplementary Figure 1 and searched for genes that harbored probably pathogenic variants across four or more families. However, no genes matched all these criteria.
We therefore switched our focus to single families. We initially examined the SM7 pedigree (Fig. 1a) from which three individuals had been sequenced. We used pre-existing linkage data from 5 SM7 individuals with ≥5 early-onset colorectal adenomas 2,3 to restrict our search to 8 shared regions of the genome. There were six non-silent coding variants present in four different chromosomal regions that were shared by the three sequenced members of SM7 (Supplementary Table 2 ). Further genotyping determined that the additional affected members of SM7 (Fig. 1a) only shared one of these variants, POLE p.Leu424Val (NM_006231; c.1270C>G). POLE encodes the polymerase and proofreading subunit of polymerase ε. Leu424 is highly conserved (Supplementary Fig. 2a) , and the leucineto-valine change is predicted to have severe functional consequences for protein activity (SIFT score = 0.01, PolyPhen-2 score = 0.993, Phylop score = 1.000, cons46 score = 607 (logarithm of odds (LOD) = 390) and MutationTaster score = 0.987).
We performed genotyping to screen for the mutation encoding the POLE L424V variant in a set of validation phase samples. These comprised A r t i c l e s A r t i c l e s 3,805 individuals of European ancestry with CRC, enriched for a family history of colorectal tumors, multiple adenomas and early-onset disease (Online Methods). For comparison, we genotyped 6,721 controls of European ancestry, of whom about two-thirds were population based and one-third was selected for absent personal history of colorectal tumors. We found 12 additional unrelated cases and no controls who were heterozygotes for the mutation encoding the L424V variant (association P = 2.46 × 10 −6 , Fisher's exact test, one tailed). In addition, POLE L424V was not present in 10,755 controls sequenced as part of the National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project (see URLs), despite >50× median read depth at the corresponding site in the genome. We confirmed that mRNA encoding the POLE L424V variant was expressed, without finding any evidence of allele-specific instability (data not shown).
The pedigrees of the 12 validation phase cases with POLE L424V are shown in Supplementary Figure 3 . They are compatible with a dominantly inherited trait. All pedigrees except one contained at least one individual with multiple or very large adenomas, multiple colorectal carcinomas or early-onset CRC. Microsatellite marker analysis provided no evidence of a recent common ancestor in these families (data not shown). All the carriers of mutations resulting in the L424V variant were found in our highly selected groups of individuals from the CORGI, multiple-adenoma and NSCCG studies (Online Methods) rather than in the individuals enrolled in our CRC clinical trials (VICTOR and QUASAR2). This suggests that the relatively severe phenotypes of the carriers of the L424V variant do not simply reflect ascertainment criteria and also shows that these mutations are likely to be a rare cause of CRC in the general population. Genotyping of additional members of these 12 families showed that all carriers of mutations encoding the L424V variant developed colorectal tumor(s) and that no tumor-free blood relatives of cases had the L424V variant. One non-carrier, from a kindred in which other affected members developed tens of adenomas or multiple carcinomas, had developed a single tiny (~0.5 mm in diameter) colorectal polyp by 33 years of age, a phenotype compatible with sporadic occurrence or an additional complex genetic predisposition in the family. On the basis of a relatively stringent definition of affected status of ≥5 colorectal adenomas, ≥1 large (>2 cm in diameter) adenoma, ≥2 colorectal carcinomas or CRC at ≤40 years of age and making the reasonable assumption that all alleles encoding the L424V variant within each family were identical by descent, the probability of each affected non-proband sharing L424V in the 12 validation phase families was determined to be 1.22 × 10 −4 after ascertainment correction.
Overall, the phenotypes of our pedigrees with the L424V variant were consistent with dominantly inherited, high-penetrance predisposition to colorectal adenoma and carcinoma, with a variable tendency to develop multiple and large tumors. Therapeutic or prophylactic colectomy had occurred in several cases, thus attenuating the phenotype, and it is also likely that some tumors were under-reported, especially in early generations. However, even allowing for these factors, tumor multiplicity seemed to vary among individuals ( Fig. 1a and Supplementary Fig. 3) . Moreover, adenomas did not in general seem to progress rapidly to carcinomas in all individuals. The histological features of the colorectal tumors from carriers of the L424V variant were unremarkable, mostly comprising conventional adenomas and carcinomas without unusual morphology or obvious site predilection in the large bowel. No conclusive evidence of a predisposition to extracolonic tumors or nontumor phenotypes was found in the families with the POLE L424V mutant (Fig. 1a and Supplementary Fig. 3) .
We examined 39 tumors from 11 carriers of the POLE L424V variant for somatic mutations. Second hits by loss of heterozygosity (LOH) involving the germline wild-type allele were found in some tumors, including adenomas ( Supplementary Fig. 4) . In contrast to the microsatellite instability seen in Lynch syndrome, all tumors were microsatellite stable (MSS), and the two carcinomas analyzed had chromosomal instability. Most tumors were screened for KRAS and BRAF driver mutations, and a subset of tumors was screened for somatic mutations in genes with established pathogenicity, including APC, CTNNB1, PIK3CA and FBXW7 (Table 1 and Supplementary Table 3 ). Mutations were found in all genes apart from CTNNB1, suggesting that the tumors at least partly followed the classical pathway of colorectal tumorigenesis. Mutations were all base substitutions. For APC, this was a notable difference from sporadic tumors in which ~60% of mutations are frameshifts 4 . Moreover, certain sites not commonly mutated in sporadic colorectal tumors seemed to be mutation hotspots, for example, codons 1114 and 1338 of APC and codon 146 of KRAS. Unlike in MUTYH-associated polyposis, where somatic driver mutations are almost all G:C>T:A changes, the tumors from our subjects showed no evidence of a predominant type of substitution in the six genes analyzed, although, at this stage, we could not exclude more subtle biases in this regard.
We then considered variants shared by the two affected individuals sequenced in our other large family, SM6. Using the same strategy as used for SM7-searching for shared functionally important variants and filtering using linkage analysis (Supplementary Table 4) -we identified two SM6 cases who shared a heterozygous POLD1 mutation encoding a p.Ser478Asn alteration (NM_002691: c.1433G>A). We also found the same variant in another proband (SM4) who had undergone whole-genome sequencing in WGS500. This variant was stably expressed at the mRNA level (data not shown) and was predicted to have a severe effect on protein function (SIFT score = 0.01, PolyPhen-2 score = 0.992, Phylop score = 0.987, cons46 score 607 (LOD = 390) and MutationTaster score = 1.000). Moreover, the equivalent of residue 478 in POLD1 is residue 428 in POLE, very close to the site of the L424V alteration (Supplementary Fig. 5 ).
We typed S478N alterations in all available members of SM6 and SM4 (Fig. 1b,c) . All carriers of the mutation encoding the S478N variant developed colorectal tumor(s), and all affected individuals (using the same criteria as described above) carried the mutation encoding the S478N variant (P = 0.008 after ascertainment correction). 
A r t i c l e s
Affected members of SM6 and SM4 shared alleles at microsatellites D19S867 and D19S904, consistent with a common ancestor. No tumor-free blood relatives of cases carried the mutation. We noted that a formally unaffected non-carrier from SM6, whose other members had multiple polyps ( Fig. 1b) , had developed one very small (<1 mm in diameter) colorectal adenoma by 43 years of age. We then used genotyping to screen for the mutation encoding the POLD1 S478N variant in the validation phase and found one additional carrier, a case diagnosed with colorectal carcinoma at age 28 years, whose father also had colorectal cancer at 44 years of age. No control carried POLD1 S478N, and the variant was also absent from the NHLBI GO Exome Sequencing Project database. The colorectal phenotypes of carriers of the POLD1 S478N variant were generally similar to those of individuals with POLE L424V ( Fig. 1 and Supplementary Fig. 3 ). However, seven affected individuals with POLD1 mutations had developed endometrial carcinoma, some at relatively young ages, and one had developed two primary brain tumors. No cases of either tumor type were present in the 13 families with POLE mutations. As a result of these findings, we screened 386 early-onset endometrial cancer cases without a reported family history of CRC for the POLD1 S478N variant, but we did not find any further carriers.
We examined 23 tumors from carriers of the POLD1 S478N variant for LOH and for the somatic mutations that had been screened for in the POLE-mutant tumors ( Table 2 and Supplementary Table 5 ). In most respects, the POLD1-mutant tumors resembled POLE-mutant tumors: second hits occurred at POLD1 by LOH involving the germline wild-type allele ( Supplementary Fig. 4 ), tumors were all MSS, carcinomas had chromosomal instability, cytosine-to-thymine substitution mutations were most common and the APC mutation spectrum was atypical compared with that of sporadic CRCs. However, there were also some possible differences: KRAS mutations tended to target codons 13 and 61 in the POLD1 mutants, as compared with codons 12 and 146 in POLE mutants, and some POLD1-mutant tumors had BRAF mutations.
Functional and structural assessment
Human POLE is the catalytic subunit of the polymerase ε (Pol ε) enzyme complex 5 . Pol ε is responsible for the synthesis of the leading strand during DNA replication. In addition to DNA-binding and polymerase domains, Pol ε has proofreading capacity through the POLE exonuclease domain. This capacity is essential for the maintenance of replication fidelity and may act, not only on newly misincorporated bases, but also on mismatches produced by non-proofreading polymerases such as polymerase α (Pol α). Leu424 is conserved in the exonuclease domain of B-class DNA polymerases ( Supplementary  Fig. 2a) , and a BLAST search against the Protein Data Bank (PDB; see URLS) showed that Leu424 maps directly to the active site of the exonuclease domain (Leu479 in yeast DNA polymerase (PDB 3IAY)) 6 . The importance of Leu424 for proofreading has been shown by alteration of the equivalent residue (p.Leu479Ser) in Saccharomyces cerevisiae polymerase δ (Pol δ; also known as Pol3). This causes a mutator phenotype similar to that seen with the pol3-01 mutant strain that has less than 0.5% of wild-type exonuclease activity 7, 8 .
POLD1 encodes the catalytic and proofreading subunit of Pol δ, the equivalent lagging-strand polymerase to Pol ε (refs. 9,10), and Pol δ may also participate in the mismatch and base excision repair pathways 11, 12 . Ser478 in POLD1 is highly evolutionarily conserved in eukaryotes, including S. cerevisiae, although, in Schizosaccharomyces pombe, the homologous amino acid is the structurally very similar cysteine (Supplementary Fig. 2b ). The substitution affecting Ser478 lies close to other alterations that result in a mutator phenotype in S. cerevisiae Pol3 (ref. 8 ), but alteration of this specific residue has not been reported. We therefore generated a construct encoding the equivalent change in the fission yeast protein and determined the effect of this change on reversion of the ade6-485 allele, which comprises a cytosine-to-guanine transversion that reverts to cytosine through base substitution 13 . The Pol3-C462N strain (encoding a variant equivalent to human POLD1 S478N) had a mutation rate 12-fold higher than a wild-type strain that was constructed using the same strategy (Table 3 and Supplementary Table 6 ). We also examined a Pol3-C462S strain expressing the equivalent of the human wild-type protein, and the encoded C462S alteration did not have a significant effect on the ade6 reversion rate.
POLE and POLD1 are related B-family polymerases that have greatest homology (23% identity and 37% similarity) over the exonuclease domain (residues 223-517 of POLE and residues 245-571 of POLD1). Mapping these two alterations onto the structure of yeast DNA polymerase revealed that they pack together at the interface between two helices that form the base of the exonuclease active site. Modeling the single-stranded DNA (ssDNA) component of T4 DNA polymerase/ exonuclease complex (PDB 1NOY) shows that POLE L424 is only ~5 Å from the ssDNA, and mutations affecting Leu424 in POLE or Ser478 in POLD1 will distort the packing of the helices, a change that is propagated through to the active site, affecting nuclease activity (Fig. 2) .
Additional POLE and POLD1 predisposition variants
We wondered whether further germline POLE and POLD1 exonuclease domain variants might predispose to colorectal tumors. We screened the corresponding genomic regions (codons 268-471 of POLE and codons 304-517 of POLD1) for germline variants in 469 1 4 0 VOLUME 45 | NUMBER 2 | FEBRUARY 2013 Nature GeNetics A r t i c l e s cases with multiple colorectal adenomas and/or familial CRC (sample sets 1 and 4 in the Online Methods). We found three heterozygous POLD1 variants, each in a single case, that were absent from publically available control databases and from the noncancer cases in WGS500: c. 981C>G (p.Pro327Leu), c.1110C>G (p.Ser370Arg) and c.1276G>A (p.Gly426Ser). Structural studies showed that both Ser370 and Gly426 were unlikely to be involved in direct DNA binding, and alterations of these residues were predicted to have only moderate functional effects. By contrast, for the P327L variant, which was identified in a 70-year-old individual with ten colorectal adenomas, there was good evidence of functional consequences. The Pro327 residue is fully evolutionarily conserved and lies on the DNA interface of the POLD1 exonuclease domain. Moreover, Pro327 in POLD1 is analogous to Pro286 in POLE, an amino acid that lies at the DNA-binding interface and is affected by somatic mutations in sporadic CRCs ( Fig. 2 and Supplementary Table 7) .
POLE and POLD1 somatic mutations in sporadic CRCs
There is currently little evidence of pathogenic somatic POLD1 mutations in sporadic CRCs (Supplementary Table 7 ), but there have been some reports of somatic POLE mutations in sporadic CRCs [14] [15] [16] . Of particular interest is recent sequencing by The Cancer Genome Atlas (TCGA) of 224 CRC exomes 17 . The authors highlighted mutations in POLE as important somatic changes but did not find a significant excess of mutations in the gene over background. Moreover, the importance of individual mutations was not assessed. We therefore examined the TCGA POLE data in the light of our own findings ( Table 4 and Supplementary Table 7 ). Fifteen TCGA CRCs had one or more POLE mutation at locations throughout the gene. Six of these cancers were hypermutated and/or showed MSI owing to MLH1 methylation. Two additional CRCs were MSS without hypermutation, and one of these had a mutation affecting the exonuclease domain. Notably, all of the remaining 7 POLE-mutant cancers were hypermutated and either MSS or had low-level MSI, and each of these CRCs had a mutation affecting the POLE exonuclease domain (P < 0.001, Fisher's exact test; Supplementary Table 7) . In some cancers, the mutation affecting the exonuclease domain was accompanied by a second nonsense (sample 17) or missense mutation elsewhere in the protein (Table 4) . Structural analysis showed that the exonuclease domain alterations cluster around the DNA-binding site (Fig. 2c) , including one substitution, p.Pro436Arg (p.Pro327Leu in POLD1), that lies in a disordered loop that becomes ordered upon DNA binding (sample 15; Supplementary Table 7 ). All of these alterations are predicted to have a direct effect on DNA binding and/or activity. Exonuclease domain-mutant (EDM) CRCs in the TCGA data set tended to have nonsense mutations in the APC gene, including at some of the same hotspots that we observed in tumors from the individuals with germline POLE or POLD1 mutation (Table 4 and  Supplementary Table 7) . For example, the APC p.Arg1114* alteration was found in 6 of 224 TCGA CRCs, 3 of which had POLE exonuclease domain alterations (P < 0.001, Fisher's exact test). Genome-wide analysis showed that the POLE-EDM CRCs from the TCGA data had an increased tendency to acquire all types of base substitutions compared with cancers that had POLE alterations outside the exonuclease domain and with all the other cancer in the TCGA data set. Indeed, the cancers with non-EDM POLE mutations were almost all MSI and showed no difference in mutation spectrum or frequency from MSI cancers without POLE mutations (Supplementary Table 8 ). The EDM-associated mutator phenotype did not, however, affect all substitutions equally. Hence, whereas C:G>T:A changes remained the most common type of mutation in EDM tumors, with an ~30-fold excess over other cancers, there was a particularly large (~100-fold) relative excess of G:C>T:A changes (Supplementary Table 8) . In an analysis of individual EDM CRCs (data not shown), each cancer showed this mutation spectrum, further suggesting that the exonuclease domain changes were functionally deleterious. However, within the EDM group, two CRCs had acquired very large numbers of mutations (over 6,000 each), these being the tumor with the mutation mapping to the loop that became ordered on DNA binding and the tumor that had both a mutation affecting the exonuclease domain and a truncating mutation in POLE.
Another very recent study 18 analyzed 74 CRC exomes. Although a direct comparison between large-scale sequencing studies using non-identical platforms and analysis pipelines must be performed with caution, we found that the data from this study provide support for our conclusions with the TCGA data. Although the authors did not highlight POLE in their manuscript, their data set included two hypermutated MSS cancers, both of which were EDM (with P286R variants in both A r t i c l e s cases) and had a genome-wide mutation spectrum similar to that of the EDM TCGA cancers (data not shown). We examined four tumors from our POLE L424V and POLD1 S478N carriers using an extended Ion Torrent panel targeting 150 cancer genes (Online Methods). These tumors all showed mutation spectra similar to those of the sporadic POLE-EDM cancers (Supplementary Table 8 ).
DISCUSSION
We have shown that the germline POLE mutation encoding an L424V variant predisposes to multiple colorectal adenomas and carcinomas. The allele shows dominant inheritance, apparently with high penetrance, and tumors with this variant occur principally or exclusively in the large bowel. Some individuals have a predominantly multiple-adenoma phenotype, similar to MUTYH-associated polyposis (MAP), a condition that results from defective base excision repair. In other individuals with the L424V variant, the phenotype is one of large adenomas or early-onset carcinoma, thus resembling Lynch syndrome, a condition that results from defective DNA mismatch repair. The phenotypic variation caused by L424V is also found in both MAP 19 and Lynch syndrome 20 and is consistent with the action of genetic modifiers. However, it may have other causes (for example, random mutation, different environments, reduction in risk owing to therapeutic surgery or other tumor prophylaxis, under-reporting of adenomas, especially in older family members, or premature death). Overall, the evidence strongly suggests that the mechanism of tumorigenesis caused by L424V is decreased fidelity of replication-associated polymerase proofreading, leading to an increased mutation rate by base substitution.
We have also shown that the POLD1 S478N variant predisposes to colorectal tumors, endometrial cancer and, perhaps, to brain tumors. The colorectal phenotype cannot be distinguished from that of POLE L424V mutants in the current data set. The seemingly different tumor spectrum in carriers of the POLE L424V and POLD1 S478N variants is unexplained, but similar differences are found in Lynch syndrome, in which carriers of MSH6 mutations, for example, seem relatively prone to endometrial cancer 21 . One possible explanation is that a mutator phenotype is not the only tumor-promoting consequence of POLE and POLD1-and, indeed, mismatch repair gene-mutation. 
A r t i c l e s
It is highly plausible, on the basis of theoretical considerations and the TCGA data in sporadic CRCs, that a variety of germline POLE and POLD1 mutations affecting the exonuclease domain can influence CRC risk. A strong candidate from our own analysis is the POLD1 P327L variant. The effects of these mutations might vary depending on the degree to which they impair proofreading. Other pathogenic mutations might affect the non-proofreading domains of POLE or POLD1 or might lie in genes that encode the other components of Pol ε and Pol δ (POLE2, POLE3, POLE4, POLD2, POLD3 and POLD4). Such mutations might act a little differently from those affecting the proofreading domain, for example, if they caused a tendency for the polymerase to incorporate mispaired bases into the growing strand. Of note, we have previously shown that common variation at the POLD3 locus is associated with CRC risk in the general population 22 .
Mice that carry double Pole mutations (encoding p.Asp272Ala and p.Glu274Ala alterations), affecting the exonuclease active site catalytic residues, impair proofreading and cause a base substitution mutator phenotype in both the heterozygous and homozygous states 23, 24 . Homozygote Pole mutants are specifically predisposed to developing intestinal adenomas and carcinomas. Mice with germline Pold1 mutations encoding a p.Asp400Ala alteration had a similar mutator phenotype in both the heterozygous and homozygous states, and homozygous mutant animals had a tendency to develop a variety of cancers, although, of note, the tumor spectrum differed from that of the Pole mutants, with most tumors being of cutaneous rather than intestinal origin 23, [25] [26] [27] [28] . There was also evidence of different but overlapping mutation spectra in the Pole-and Pold1-mutant animals.
The question remains whether POLE and POLD1 mutations act as classical tumor suppressors with second hits, as haploinsufficient alleles or through some hybrid mechanism, such as loss of a specific protein function. We cannot resolve this issue yet from our own data or the TCGA findings, but we note the following: (i) second hits do occur in some of the tumors, including early lesions, from affected individuals in our study, at frequencies greater than the background level expected from other studies 29 , but many POLE-or POLD1-EDM tumors do not have identified second hits (Supplementary Tables 3, 5 and 7); (ii) the alleles encoding the POLE L424V and POLD1 S478N variants produce stable mutant mRNA, and there is no evidence from our data that protein-truncating or null POLE or POLD1 mutations predispose to tumors; and (iii) biallelic Pole or Pold1 mutations that cause complete loss of enzyme function are probably cell lethal in mice. A possible mechanism to consider is one in which mutations are only pathogenic when they couple functional polymerase activity to nonfunctional proofreading in the same molecule.
When added to the DNA mismatch repair defects that underlie Lynch syndrome and the base excision repair defects that cause MAP, the mutations in POLE and POLD1 emphasize the critical role of replication errors and coupled repair of base pair-level mutations in predisposition to colorectal and endometrial cancers. This is in contrast to cancers of the breast and ovary, in which double-stranded DNA break repair is more important in predisposition. POLE L424V and POLD1 S478N variants can be easily tested for and should be considered in any individual with an unexplained personal or family history of multiple or large colorectal adenomas and/or multiple or early-onset colorectal (or endometrial) carcinoma. Although further data are required, it may be prudent in the short term to manage mutation carriers in a fashion intermediate between the care for Lynch syndrome and MAP, with regular and frequent colonoscopic polypectomy and consideration of prophylactic surgery. 
METhODS
Methods and any associated references are available in the online version of the paper.
ONLINE METhODS
Samples. All cases and controls were UK residents and had self-reported European ancestry. For most individuals, large-scale genotyping data were available that allowed ancestry clustering with HapMap Utah residents of Northern and Western European ancestry (CEU) samples to be verified. None of the groups described overlapped. All studies were performed with UK national ethical committee approval (MREC/06/Q1702/99). All participants provided written informed consent or samples were irreversibly anonymized.
Discovery phase cases. Cases were obtained from the CORGI study 30 . The study has recruited through clinical genetics departments from throughout the UK since 1999 and has to date enrolled 1,698 families. General eligibility criteria for the study are given here. Discovery phase cases were selected from among the set of CORGI probands for a disease phenotype that was most strongly reminiscent of a high-penetrance predisposition. We specifically enriched for multiple tumors and/or an early age of presentation and/or multiple family members with CRC or adenomas. Formal criteria were not set owing to the impossibility of weighing these different features against each other and the heterogeneity of clinical data (for example, comparing an individual who had had fewer adenomas but also a colectomy to one who had more adenomas but only polypectomies). Our prioritization resulted in the identification of a set of 15 unrelated individuals who had been diagnosed with ≥10 colorectal tumors before the age of 60 years (Supplementary Table 1 ). All individuals had CRC or a first-or second-degree relative with CRC, but they were not otherwise selected for family or personal history of other tumor types. All individuals had been screened for APC and MUTYH mutations by their local Genetics Service, and Lynch syndrome had been screened for by examining microsatellite instability and/or mismatch repair protein expression in tumors and/or by direct testing for MSH2, MLH1, MSH6 and PMS2 mutations. DNA from these samples and five additional family members was sequenced across the entire genome as part of the Oxford University-Illumina WGS500 collaboration (Supplementary Note).
Validation phase cases. These samples comprised the following non-overlapping collections, all comprising individuals of European descent from the UK.
1. Multiple adenoma cases. These comprised 271 individuals who had developed ≥5 colorectal adenomas at any age, irrespective of family history of colorectal tumors. Germline APC and MUTYH mutations had been excluded. These individuals were recruited principally from St. Mark's Hospital, London, and were included in the study irrespective of other personal or family history. The mean number of adenomas was 16 (range of 4-65), mean age of presentation was 54 (range of 23-80); 21% had had CRC; and 31% reported a family history of CRC.
2. CORGI cases. These comprised 1,476 individuals from the CORGI study 30 . All recruits had developed CRC at an age of ≤80 years and/or 'significant' colorectal adenoma(s) that fulfilled one or more of the following criteria: (i) ≥3 in number; (ii) severe dysplasia; (iii) villous histology; and (iv) presentation at <45 years of age. All adenoma-only cases (n = 503) had a first-or second-degree relative with CRC. The mean age of participants was 58 years (range of 18-80 years).
3. National Study of Colorectal Cancer Genetics (NSCCG). CRC cases (n = 300) were selected from the main NSCCG study to be aged <55 at diagnosis and to have at least one first-degree relative affected with CRC. The main NSCCG study recruited any individual with CRC from oncology clinics throughout the UK 31 .
4. Whole-genome sequencing. Case data were obtained using the Complete Genomics platform 32 from 198 CRC cases previously selected for early age of presentation and family history from the CORGI and NSCCG studies.
5. VICTOR/QUASAR2 samples. These comprised 1,560 cases from the VICTOR and QUASAR2 clinical trials of stage II/III CRC treated with curative intent 33 . VICTOR was a post-primary therapy randomized controlled trial of rofecoxib, and QUASAR2 is a randomized trial of adjuvant 5-fluorouracil with or without bevacizumab. The mean age of subjects derived from these trials was 61 years (range of 44-70 years).
Validation phase controls. These comprised the following collections, all made up of white individuals from the UK.
1. CORGI. Controls included 1,666 spouses or partners of CORGI cases and reported no personal or family history of colorectal tumors.
2. 1958 Birth Cohort sequencing set. Controls 34 (n = 300) had undergone whole-exome sequencing.
3. Population controls. These controls (n = 3,812) were obtained from the population-based, publicly available 1958 Birth Cohort and National Blood Service 35 sample sets.
4. GLACIER. Controls without cancer (n = 943) were derived from the GLACIER study of lobular breast cancer predisposition and were cancer-free spouses, partners or friends (E.J.S., I.T. and R.R., unpublished data).
5. Exome Variant Server. Although not used for primary statistical comparisons, additional population-based control data were derived from the Exome Variant Server (NHLBI GO Exome Sequencing Project).
Endometrial cancer cases. Cases (n = 386) with primary carcinoma of the endometrium and without a family history of CRC were derived from the National Study of Endometrial Cancer Genetics (NSECG) that recruited white UK cases with endometrial cancer under the age of 70 years 36 .
Germline genotyping and mutation screening. Whole-genome sequencing data for POLE, POLD1 and other variants within regions of linkage 2,3 were validated by bidirectional Sanger sequencing using standard methods (details available upon request), and variants were identified both automatically and manually in the Mutation Surveyor program (Soft Genetics). For screening the validation phase samples, we designed KASPar 37 allele-specific singlenucleotide variant (SNV) primers to detect the POLE L424V and POLD1 S478N variants (Supplementary Fig. 6 ) and included two known variant samples in each run to facilitate genotype clustering (details available upon request). All potential L424V and S478N variants detected were subsequently examined by bidirectional Sanger sequencing. For screening the full regions encoding exonuclease domains in POLE (codons 269-471) and POLD1 (codons 304-517), bidirectional Sanger sequencing was used (details available upon request).
Expression of the mutant alleles encoding the POLD1 S478N and POLE L424V variants. mRNA was extracted from pelleted untransformed lymphocytes from one affected individual from SM6 and two affected individuals from SM7 using the RNeasy kit (Qiagen) following the manufacturer's instructions. RNA was treated with DNaseI (Fermentas) and converted into cDNA using the High-Capacity cDNA reverse transcription kit (Applied Biosystems). cDNA was tested in triplicate using the KASPar genotyping assays described. Heterozygous genomic DNA samples were run alongside these samples together with cloned alleles in various mixtures to determine whether the mRNA expression of the two alleles was balanced.
LOH and common ancestor analysis. Microsatellites mapping close to POLE (D12S1723, D12S1628, D12S357 and D12S1638) or POLD1 (D19S867, D19S904 and D19S907) were analyzed in the Gene Marker program (Soft Genetics) and used to assess whether the alleles encoding the L424V and S478N variants were derived from a common ancestor (details of PCR conditions available from authors). LOH was assessed using the same set of microsatellites. LOH was scored if the intensity of any allele was reduced by ≥50% relative to the other allele after taking into account the relative allelic intensities in paired constitutional DNA. In the case of discordance between microsatellites, precedence was given to the one closest to POLE or POLD1. For a small subset of POLD1-mutant tumors, LOH analysis was performed across the genome using the Illumina GoldenGate HumanLinkage system (Panel V). Briefly, ~1 µg of tumor DNA and paired constitutive DNA were amplified per the manufacturer's instructions and hybridized separately to Sentrix BeadArrays overnight. Each chip was then washed, stained and scanned immediately using an Illumina BeadArray reader. GenomeStudio software (Illumina) was used to identify regions with LOH and/or copy-number changes. It should be noted that some tumors in the set analyzed were very small, and contamination by normal cells may have obscured LOH in some cases. Similarly, it was not possible to screen the large POLE and POLD1 genes for second hits other than LOH owing to limiting tumor material.
Somatic CRC driver mutation screening: Ion Torrent cancer hotspot panel. Using the Ion Torrent cancer hotspot panel, we screened CRC-associated mutations for somatic changes in tumors from carriers of the POLE L242V and POLD1 S478N variants using direct sequencing. Owing to limited quantities of DNA from the formalin-fixed, paraffin-embedded tumors available from our subjects, we focused on relatively common somatic mutations for which there was excellent pre-existing evidence of pathogenicity. Specifically, on the basis of the existing literature and databases, we regarded the following as pathogenic: APC (reference sequence NM_000038), protein-truncating mutations between codons 167 and 1580; CTNNB1 (NM_001904), missense mutations at codons 32, 33, 34, 37, 41 or 45; KRAS (NM_004985), missense mutations at codons 12, 13, 61 or 146; BRAF (NM_004333), V600E variant; PIK3CA (NM_006218), missense mutations at codons 345, 420, 542, 545, 546, 1025 or 1047; and FBXW7 (NM_033632), protein-truncating mutations and missense mutations at codons 465, 479, 505 or 582. TP53 was not analyzed because of the uncertain pathogenicity of some missense variants. Mutations were called using Ion Reporter (Invitrogen), and bam files were also inspected manually to remove likely artifacts and to detect any mutations-especially insertions and deletions in APC-that were not called by the Ion Reporter software. KRAS and BRAF mutations were also screened for in an extended sample set using Sanger sequencing.
Somatic mutation spectrum screening: Ion Torrent cancer gene custom panel. One tumor from a carrier of the POLE L424V variant (SM7) and three tumors from carriers of the POLD1 S478N variant (two from a member of SM6 and one from a member of SM4) were screened for exonic variants in a custom panel of 150 cancer-related genes using the Ion Torrent Ampliseq method (details available upon request). After excluding the above known CRC driver genes and known polymorphisms, the somatic mutation spectrum was determined. All but two indel mutations were substitutions.
Fission yeast strain construction and mutation rate assays. Strains used in this study are listed in Supplementary Table 6 . Standard genetic methods were used for strain construction 38 . The pol3-C462N mutant strain (encoding a variant equivalent to human POLD1 S478N) was constructed by amplifying pol3 segments with primer combinations of primers 1075 and 1077 and primers 1076 and 1078 (Supplementary Table 6 ). The products were purified, annealed and amplified using primers 1075 and 1076. The product was digested with BamHI and AscI and inserted into pFA6a-kanMX6 (ref. 39 ). The pol3-C462S strain (encoding a protein equivalent to wild-type human POLD1) was constructed in the same way using initial primer combinations of primers 1075 and 1079 and primers 1080 and 1076. As a control, a pol3 + (wild-type) strain was also constructed using the same procedure, using primers 1075 and 1076 to amplify the wild-type sequence. Plasmids were integrated into the pol3 locus after linearization with CspCI and selecting for G418 resistance. Constructs were verified by sequencing. Mutation rates of the ade6-485 allele in different strain backgrounds were determined by fluctuation analysis as previously described 40 . Eleven cultures were used for each experiment, and plates were scored after 7 d. Mutation rates were calculated using the MSS-Maximum Likelihood Estimator 41 .
Structural analysis. Alterations in human POLE and POLD1 were visualized in PyMOL (see URLs) on the catalytic subunit of the yeast DNA polymerase δ (PDB 3IAY)), with the ssDNA component of the T4 polymerase complex (PDB 1NOY) modeled into the exonuclease active site.
Details on other methods are provided in the Supplementary Note.
